These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 23657801)

  • 1. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
    Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
    Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
    Kanwal A; Singh SP; Grover P; Banerjee SK
    Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fluorescence method for measurement of glucose transport in kidney cells.
    Blodgett AB; Kothinti RK; Kamyshko I; Petering DH; Kumar S; Tabatabai NM
    Diabetes Technol Ther; 2011 Jul; 13(7):743-51. PubMed ID: 21510766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
    Pajor AM; Randolph KM; Kerner SA; Smith CD
    J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural selectivity of human SGLT inhibitors.
    Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
    Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
    Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transport.
    Castaneda F; Kinne RK
    Mol Cell Biochem; 2005 Dec; 280(1-2):91-8. PubMed ID: 16311909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a fluorescent glucose derivative 1-NBDG and its application in the identification of natural SGLT1/2 inhibitors.
    Kao TY; Wu HW; Lee SS; Liang PH; Guh JH; Hsu LC
    J Food Drug Anal; 2021 Sep; 29(3):521-532. PubMed ID: 35696243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
    Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
    Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
    Hummel CS; Lu C; Loo DD; Hirayama BA; Voss AA; Wright EM
    Am J Physiol Cell Physiol; 2011 Jan; 300(1):C14-21. PubMed ID: 20980548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors.
    Wu SH; Yao CH; Hsieh CJ; Liu YW; Chao YS; Song JS; Lee JC
    Eur J Pharm Sci; 2015 Jul; 74():40-4. PubMed ID: 25819489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
    Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
    J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.
    Putapatri SR; Kanwal A; Banerjee SK; Kantevari S
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1528-31. PubMed ID: 24556379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
    Takasu T; Yokono M; Tahara A; Takakura S
    Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Na
    Koepsell H
    Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of SGLT1 and SGLT2 inhibitors.
    Rieg T; Vallon V
    Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.